What are the first signs of retinitis pigmentosa?

The most common early sign is night blindness — difficulty seeing in low light or adjusting from bright to dim. Many people also notice they bump into things at the edges of their vision before they are aware of any change, because peripheral loss is gradual.

Is there a treatment for retinitis pigmentosa?

There is no universal cure yet, but the field is moving quickly. One gene therapy, voretigene neparvovec, is FDA-approved for RP caused by RPE65 mutations, and several gene-agnostic and gene-specific therapies are in late-stage trials. Because RP is driven by more than 100 different genes, the right path depends heavily on a person's specific genetic diagnosis.

Retinitis pigmentosa, in plain light

The first thing it takes is the stars.

Q: What is retinitis pigmentosa?

Retinitis pigmentosa is a group of inherited diseases that slowly damage the light-sensing cells of the retina. The rod cells, which handle night and side vision, are usually affected first, so the earliest signs are trouble seeing in dim light and a gradually narrowing field of view.

Retinitis pigmentosa quietly dims night vision and narrows the edges of sight. We made StellaVision to explain it clearly, follow the research honestly, and help families see the whole picture.

Understand RP Where research stands

~1 in 4,000people live with RP worldwide

100+different genes can cause it

Night visionis usually the first sense affected

The basics

What is retinitis pigmentosa?

Retinitis pigmentosa, or RP, is not one disease but a family of inherited conditions that slowly damage the retina — the layer of light-sensing cells at the back of the eye. The rod cells, which give us vision in dim light and at the edges of our sight, are usually affected first. The cone cells, responsible for sharp central and color vision, are typically affected later.

Because the change is gradual and starts at the periphery, RP is often present for years before anyone notices. It is progressive, it varies enormously from person to person, and — critically — what happens next depends on which gene is involved.

Early signs

What people tend to notice first

RP rarely announces itself. These are the changes families most often recognize in hindsight.

Night blindness

Trouble seeing in low light, or slow adjustment moving from bright places to dark ones. Usually the earliest sign.

Narrowing side vision

Bumping into things at the edges, or missing objects and people just outside the center of view as the visual field contracts.

Slow light adjustment

Glare sensitivity and a longer-than-usual pause for the eyes to settle when lighting changes suddenly.

Why genetics decides everything

RP isn't one problem. It's a hundred.

More than a hundred different genes can cause retinitis pigmentosa, and the gene a person carries shapes how their RP progresses and which therapies could ever apply to them. Two people with the same diagnosis can have completely different roads ahead.

That is why a genetic diagnosis matters so much. It turns "retinitis pigmentosa" from a label into something specific enough to match against research, trials, and emerging treatments. Until the gene is known, almost every targeted decision waits.

As of 2026

Where the research stands

For most of history, RP offered little beyond low-vision aids. That is changing. Here is an honest snapshot of the approaches now moving through the clinic.

Approved

Gene replacement for RPE65

Voretigene neparvovec is FDA-approved for inherited retinal disease caused by RPE65 mutations — the first gene therapy of its kind, and proof the approach can work.

Late-stage

Gene-agnostic modifier therapy

Therapies designed to work across many genotypes, such as OCU400, are in pivotal Phase 3 trials, with key readouts expected in the near term.

Late-stage

Optogenetics & cell therapy

Approaches that aim to restore light sensitivity or replace lost cells — independent of the underlying gene — are reporting multi-year follow-up data in advanced RP.

Emerging

Gene-specific & neuroprotective programs

Targeted programs for genes like RPGR (X-linked RP), plus drugs designed to slow degeneration by protecting cells, are advancing through earlier trials.

This is general information, not medical advice, and the field moves fast. Eligibility depends on your specific genetic diagnosis and clinical picture — decisions belong with your eye-care team. For live, authoritative detail, see ClinicalTrials.gov and the Foundation Fighting Blindness.

Why we built this

The mission

When RP enters a family, the hardest part is how little of it you can see coming.

StellaVision started at a kitchen table, after retinitis pigmentosa entered our lives. One of us is an engineer; all of us were suddenly trying to understand a disease that hides at the edges of vision and bifurcates a hundred different ways.

So we are building two things. This site — open to everyone — gathers clear knowledge, current research, and honest framing about RP. Behind it sits a private, consent-first platform that helps a family track vision over time and, when they choose, hand researchers a clean, ready cohort. We can't run the wet labs. What we can do is reduce friction: better data, faster matching, and a clearer line of sight for the people doing the science.

Go deeper

Trusted starting points

Organizations and tools we point families toward. We are not affiliated with them.

Foundation Fighting Blindness → Research news, clinical-trial pipeline, and the My Retina Tracker registry. ClinicalTrials.gov → The official registry of trials worldwide — search by condition and gene. National Eye Institute → Plain-language medical overview of RP from the NIH.